Sanofi-aventis announced that Jevtana Injection is now available in the United States for patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-based treatment regimen.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease.
Most organisms need iron to survive, but too much iron is toxic, and can cause fatal organ failure. The same is true inside cells, where iron balance must also be maintained.
New research provides a theoretical model that compares the transport characteristics of straight- and branched-chain polymers in smooth channels as well as in channels whose walls interact with the polymer, work that could aid in delivering drugs at a controlled rate in the body.
A major breakthrough in how to target and destroy the most malignant and aggressive brain cancer cells has been made by researchers at Wake Forest University Baptist Medical Center.
Researchers have found a new mechanism that explains how certain immune cells are activated to create protective antibodies against infections or pathological antibodies such as those present in autoimmune diseases like lupus and rheumatoid arthritis.
Genzyme Corp. and Isis Pharmaceuticals Inc. said their cholesterol drug candidate mipomersen proved effective at significantly cutting patients' bad cholesterol levels in two late-stage studies.
Health care reform hits another milestone next month, with new provisions that include a coverage expansion for young adults and restrictions on an insurer's ability to impose annual coverage limits or to reject children with pre-existing medical conditions.
The stock has fallen nearly 6 percent over the last month since speculation emerged that Sanofi-Aventis was eyeing Cambridge, Mass.-based Genzyme, maker of the Cerezyme and Fabrazyme drugs to treat genetic diseases.
Pfizer Inc. reported a 9 percent rise in second-quarter profit, trouncing Wall Street expectations as revenue jumped 58 percent due to favorable currency rates and its mega-acquisition of fellow drugmaker Wyeth last October.
Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed each year.
Affymetrix, Inc. announced that it will develop and commercialize the Axiom Chinese myDesign Genotyping Array, the first product that provides maximum power for genome-wide association studies specifically on Chinese populations.
Luminex Corporation announced the global launch of MAGPIX, an analytical instrument that is capable of performing up to 50 tests on a single sample and providing nearly 5,000 data points in under an hour.
Telormedix announced the start of a collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH) on a pilot study using Telormedix’s adjuvant, TMX-201, in connection with immunization for malaria and Buruli ulcer.
Cornerstone Therapeutics Inc. announced that it has licensed to Targacept, Inc. the worldwide rights to its nicotinic-receptor based patents and library of preclinical compounds that target the alpha-7 or other nicotinic receptors.